AzTrials
AzTrials

HyperalgesiaPhase 4NCT03225690

Prevention of Hyperalgesia With Epidural Morphine

A Phase 4 study testing Morphine and Serum physiologic in people with Hyperalgesia, run by Cukurova University at 1 site in Turkey (Türkiye).

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

American Society of Anaesthesiologist physical status (ASA) I-III 105 patients who undergoing major abdominal surgery in obstetric and gynaecology clinic were recruited to this study. Patients were randomized into the 3 groups. Lumbar epidural catheter will be inserted to the all patients. Read more about this study

Who is it for?
Ages 20 to 65 years, women onlyHealthy volunteers can take part
Conditions the study is for
Hyperalgesia
What is being tested?
Morphine and Serum physiologic
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
105 participants
Where
1 siteTurkey (Türkiye)
Study dates
19 Jul 2017to 1 Dec 2018
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 20 to 65 years
  • Women only
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • ASA I-III patients
  • Patients who undergoing major abdominal surgery

Who cannot join

  • ASA IV and up
  • Coagulopathy

Trial locations and contacts

1 site in 1 country.

Turkey (Türkiye)1 site, 1 recruiting
  • Çukurova University Balcalı Hospital

    Adana, 01380

    Çukurova University B Hospital

    Recruiting

Other trials in Turkey (Türkiye)

About this study

Official title: Does Preemptive Epidural Morphine Prevent Remifentanil Induced Hyperalgesia

American Society of Anaesthesiologist physical status (ASA) I-III 105 patients who undergoing major abdominal surgery in obstetric and gynaecology clinic were recruited to this study. Patients were randomized into the 3 groups. Lumbar epidural catheter will be inserted to the all patients. After than anaesthesia induction will provide with 2 mg/kg propofol and 0.6 mg/kg rocuronium. Desflurane and azot protoxit (N2O)-O2 will use for anaesthesia maintenance. During surgical operation, 0.3 microgram/kg/h remifentanil infusion will continuous till the end of surgery. In group I, 2 ml serum physiologic (0.9 NaCL)will apply from epidural catheter before surgical incision. In group II, 1 mg morphine will apply from epidural catheter before surgical incision. In group III, 1 mg morphine will apply from epidural catheter at the time point of peritoneum is closed. Epidural patient controlled analgesia will provide with bupivacaine for postoperative analgesia. Postoperative pain will be assessed with numerical pain scale. Postoperative analgesic requirement will be calculated. Hyperalgesia will detect with algometer and von Frey ligaments.

Read the detailed description

This randomized, double blind, controlled study will perform after obtaining informed consent and ethics approval. American Society of Anaesthesiologist physical status (ASA) I-III 105 patients who undergoing major abdominal surgery in obstetric and gynaecology clinic were recruited to this study. Patients were randomized into the 3 groups with computerized randomization programme. Lumbar epidural catheter will be inserted to the all patients. After than anaesthesia induction will provide with 2 mg/kg propofol and 0.6 mg/kg rocuronium. Desflurane and N2O-O2 will use for anaesthesia maintenance. During surgical operation, 0.3 microgram/kg/h remifentanil infusion will continuous till the end of surgery. In group I, 2 ml serum physiologic (0.9 NaCL)will apply from epidural catheter before surgical incision. In group II, 1 mg morphine will apply from epidural catheter before surgical incision. In group III, 1 mg morphine will apply from epidural catheter at the time point of peritoneum is closed. Epidural patient controlled analgesia will provide with bupivacaine for postoperative analgesia. Postoperative pain will be assessed with numerical pain scale. Postoperative analgesic requirement will be calculated. Hyperalgesia will detect with algometer and von Frey ligaments.

Conditions
Hyperalgesia
Being tested
Morphine, Serum physiologic
Medical subject headings
Hyperalgesia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • MorphineDrug

    Also called Group I-II

    Prevention of remifentanil induced hyperalgesia

  • Serum physiologicDrug

    Also called Group III

    For placebo, serum physiologic will use

Study groups in NCT03225690
Study groupRoleWhat they receive
serum physiologicPlacebo comparator2 ml serum physiologic will apply via epidural catheter before surgical incision.
Receives: Drug: Serum physiologic
Preemptive MorphineActive comparator1 mg morphine will apply via epidural catheter before surgical incision.
Receives: Drug: Morphine
MorphineActive comparator1 mg morphine will apply via epidural catheter before at the time point of the peritoneum closed.
Receives: Drug: Morphine

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Postoperative analgesic requirement

    Calculation of epidural bupivacain consumption

    Measured: Till the postoperative 24th hour.

Secondary outcomes (1)
  1. Algometer values

    Postoperative pain will detect with algometer

    Measured: Till the postoperative 24th hour.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Jul 2017
  2. Study start19 Jul 2017
  3. Primary completion1 Dec 2018 (estimated)
  4. Study completion1 Dec 2018 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Care provider
Enrolment
105 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03225690
Sponsor's protocol ID
Hyperalgesia
Status last verified
Nov 2017
First submitted
2 Jun 2017
Last updated
5 Mar 2018
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Morphine and Serum physiologic in people with Hyperalgesia, run by Cukurova University at 1 site in Turkey (Türkiye).

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 5 Mar 2018. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Ebru Biricik (5052420223, ebrubiricik01@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Postoperative analgesic requirement (time frame: Till the postoperative 24th hour.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Mar 2018.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in